So we defined cluster 2 as an immunosensitive/senescence intermediate subtype, and the validation in the IMvigor210 dataset further confirmed the better benefit of immunotherapy for PD‐L1 in cluster 2 CRC patients. This evidence concerns the gene CD274 and colorectal carcinoma.